Prestige Consumer Healthcare Inc. has agreed to purchase the Breathe Right® nasal‑strip brand and a portfolio of other established consumer‑health brands from Foundation Consumer Healthcare for $1.045 billion, or roughly $900 million after an estimated $150 million in tax benefits. The deal gives Prestige a dominant position in the sleep and breathing category, adding a product that is the market leader in nasal strips and a top children’s cough‑and‑cold brand, Dimetapp®.
The acquisition expands Prestige’s portfolio into a new category that complements its existing niche leaders—Dramamine, Fleet and Monistat—while providing a platform for future brand building. Management said the transaction fits the company’s disciplined M&A framework, citing the strong gross and EBITDA margins of the acquired brands and the opportunity to leverage Prestige’s distribution and marketing capabilities. The purchase will be financed with cash on hand and a new term‑loan facility, and the transaction is expected to close in the first half of fiscal 2027, subject to customary regulatory and closing conditions.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.